Selective acyl-coenzyme A:cholesterol acyltransferase (ACAT) inhibitor (IC50
= 0.073 μ
M). Lowers non-high density lipoprotein (HDL)-cholesterol and increases HDL-cholesterol concentrations in rats with pre-established dyslipidemia. Orally active. Also inhibits Golgi-associated LPL acyltransferase (LPAT) activity (IC50
= 15 μ
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
In vivo evidence that the lipid-regulating activity of ACAT inhibitor CI-976 in rats is due to inhibition of both intestinal and liver ACAT.
Krause et al.
J.Lipid Res., 1993;34:279
Therapeutic potential of ACAT inhibitors as lipid lowering and anti-atherosclerotic agents.
Sliskovic and White
The citations listed below are publications that use Tocris products. Selected citations for CI 976 include:
Showing Results 1 - 2 of 2